Regulation targets of hsa-miR-1-3p in cancer:
TCGA Bladder urothelial carcinoma (BLCA)
TCGA Breast invasive carcinoma (BRCA)
TCGA Brain Lower Grade Glioma (LGG)
TCGA Cervical and endocervical cancers (CESC)
TCGA Colorectal cancer (COAD)
TCGA Esophageal cancer (ESCA)
TCGA Head and Neck squamous cell carcinoma (HNSC)
TCGA Kidney renal cell cancer (KIRC)
TCGA Kidney papillary renal cell cancer (KIRP)
TCGA Liver hepatocellular carcinoma (LIHC)
TCGA Lung cancer (LUAD)
TCGA Lung squamous cell carcinoma (LUSC)
TCGA Ovarian serous cystadenocarcinoma (OV)
TCGA Pancreatic cancer (PAAD)
TCGA Prostate cancer (PRAD)
TCGA Sarcoma (SARC)
TCGA Stomach adenocarcinoma (STAD)
TCGA Thyroid carcinoma (THCA)
TCGA Uterine Corpus Endometrial Carcinoma (UCEC)
Hecker N. 2012 Bladder cancer (GSE40355)
Enerly E. 2011 Breast Cancer Subtypes (GSE19783)
Pizzini S. 2013 Colon cancer (GSE35834)
Nishida N. 2012 Colon cancer (GSE35602)
Michael F Ochs. 2013 Head and Neck Squamous Cell Carcinoma (GSE33232)
Burchard J. 2010 Hepatocellular Carcinoma (GSE22058)
Toffanin S. 2012 Hepatocellular Carcinoma (GSE20596)
Thurnherr T. 2016 Hepatocellular Carcinoma (GSE62044)
Taylor BS. 2010 Prostate cancer (GSE21034)
Enriched cancer pathway
Genes under regulation
P value
Hippo signaling pathway
2 genes: WWC1, WNT3
0.04149